About
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.
Current Value
$9.301 Year Return
Current Value
$9.301 Year Return
Key Details
Market Cap
$1.57B
P/E Ratio
-129.71
1Y Stock Return
-44.90%
1Y Revenue Growth
8.70%
Dividend Yield
0.00%
Price to Book
1.5
Strategies that include CERT
Double maintains 3 strategies that include CERT - Certara, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
US 1000
Medium risk
$33.0K
This strategy tracks a market-cap-weighted index of the 1000-largest US companies. It offers broad exposure to the US equity market, encompassing a diverse range of sectors and industries. By investing in this fund, you gain access to the performance of large and well-established companies within the US economy.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
1000
US Small Cap
High risk
$9.2K
This strategy tracks a market-cap-weighted index of primarily small-cap US stocks, representing a small portion of the total market. This strategy focuses on the growth potential of smaller companies, offering investors targeted exposure to this dynamic segment of the US equity market. With a diversified portfolio of holdings it provides a broad approach to small-cap investing.
Top Sector
Financials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
595
Stock's related to CERT
The stocks that are correlated to CERT - Certara, Inc. are SDGR, ADPT, SLP, CRL, ABCL
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
S SDGRSchrödinger, Inc. | 49.73% | $1.38B | -27.56% | 0.00% |
| 47.40% | $1.10B | +171.43% | 0.00% | |
| 46.43% | $478.50M | -49.91% | 0.51% | |
| 45.98% | $7.21B | -43.76% | 0.00% | |
| 45.61% | $622.79M | -52.50% | 0.00% | |
J JOEThe St. Joe Co. | 45.43% | $2.63B | -19.91% | 1.23% |
C CRSRCorsair Gaming, Inc. | 44.47% | $772.78M | -37.38% | 0.00% |
| 43.94% | $1.69B | -43.02% | 3.27% | |
M MTUSMetallus, Inc. | 43.91% | $518.77M | -44.73% | 0.00% |
T TREXTrex Co., Inc. | 43.84% | $5.94B | -41.64% | 0.00% |
| 43.49% | $2.68B | +21.00% | 0.00% | |
| 43.36% | $3.16B | -48.67% | 3.69% | |
| 43.05% | $1.18B | -15.60% | 0.00% | |
| 42.81% | $5.98B | -7.18% | 0.00% | |
| 42.71% | $283.97M | -38.11% | 0.00% | |
F FTVFortive Corp. | 42.61% | $23.01B | -19.28% | 0.49% |
C CTSCTS Corp. | 42.46% | $1.12B | -15.85% | 0.44% |
T TECHBio-Techne Corp. | 42.37% | $8.67B | -18.18% | 0.61% |
| 42.28% | $1.57B | -33.22% | 0.00% | |
| 42.19% | $29.57B | -29.70% | 0.00% | |
ETF's related to CERT
The ETFs that are correlated to CERT - Certara, Inc. are CPRJ, IWC, IBB, RSPA, GSSC
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 55.77% | $48.65M | 0.69% | |
| 50.16% | $809.63M | 0.6% | |
| 49.78% | $5.70B | 0.45% | |
| 49.58% | $294.73M | 0% | |
| 48.79% | $521.56M | 0.2% | |
| 48.61% | $2.79B | 0.07% | |
| 48.60% | $176.51M | 0.35% | |
| 48.57% | $48.48M | 0.5% | |
| 48.55% | $79.87B | 0.06% | |
| 48.33% | $987.53M | 0.75% | |
| 48.30% | $11.17B | 0.03% | |
| 48.27% | $1.12B | 0.31% | |
| 48.22% | $11.24B | 0.07% | |
| 48.21% | $63.84B | 0.19% | |
| 48.11% | $16.19B | 0.04% | |
| 48.06% | $1.24B | 0.1% | |
| 47.91% | $582.47M | 0.38% | |
| 47.84% | $5.92B | 0.18% | |
| 47.83% | $3.38B | 0.15% | |
| 47.75% | $6.49B | 0.18% | |
News
SeekingAlpha
Discover why Certara, Inc.'s strong Q4 results and strategic acquisition offer potential for investors. Click for my updated look at CERT stock prospects.
Yahoo
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-makingRADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numerous advanceme
Yahoo
Certara, Inc. ( NASDAQ:CERT ), is not the largest company out there, but it saw significant share price movement during...
Yahoo
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Yahoo
We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Certara, Inc. (NASDAQ:CERT) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under pressure, with the Russell small cap index […]
Yahoo
McKemey joins Certara to accelerate growth of its strategic drug development solutionsRADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformatio
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds